Basic knowledge of molecular-targeted therapy in allergic diseases

Abstract

Molecular-targeted drug refers to the therapeutic drugs developed to target specific molecules involved in the pathogenesis of diseases. It consists of high molecular weight compounds such as monoclonal antibodies and low molecular weight compounds such as JAK inhibitor and PDE4 inhibitor.

Since molecular-targeted drug targets specific molecules involved in pathogenesis, it often dramatically improves symptoms in patients resistant to conventional treatments. On the other hand, allergic diseases are not homogeneous but consist of a heterogeneous population. Therefore, some patients respond well to specific molecular-targeted drug, and patients do not. It is necessary to stratify the patients with allergic diseases based on pathological mechanisms and select the optimal treatment for each subgroup.